Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Mass General Brigham Ventures

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 11
Average round size
The average size of a deal this fund participated in
Portfolio companies 11
Lead investments 3
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Therapeutics
  • Pharmaceutical
  • Life Science

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Mass General Brigham Ventures:
Typical Co-investors
Mass General Brigham Ventures is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Mass General Brigham Ventures:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ARES International China, Jiangsu, Taiwan
Blue Elephant Capital Beijing, Beijing, China
BtoBfactory Ventures Community of Madrid, Madrid, Spain
Chengdu Technology Transfer Group Chengdu, China, Sichuan
ID Global Corporation New Zealand, Wellington, Wellington
Keyrus France, Ile-de-France, Levallois-perret
Southern Africa Innovation Support -
Syncom Venture Partners Maryland, Silver Spring, United States
Wing Capital Group Milwaukee, United States, Wisconsin

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

SwanBio Therapeutics

$56M18 May 2022 Lower Merion Township, Pennsylvania, United States


Health Care
$50M13 Jan 2022 Seattle, Washington, United States

Garuda Therapeutics

Life Science
$72M23 Sep 2021 Natick, Massachusetts, United States

Amolyt Pharma

Health Care
$80M16 Sep 2021 Écully, Rhone-Alpes, France

ROME Therapeutics

Health Care
$77M14 Sep 2021 Cambridge, Massachusetts, United States

Lyndra Therapeutics

Clinical Trials
Health Care
$60M24 Jun 2021 Watertown, Massachusetts, United States

Affinia Therapeutics

Health Care
Life Science
$110M03 May 2021 Massachusetts, United States

Carta Healthcare

Health Care
Machine Learning
$17M07 Apr 2021 Palo Alto, California, United States

SeQure DX

$17M02 Apr 2021 Waltham, Massachusetts, United States
Garuda Therapeutics Raises $72M in Series A Financing

– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Mass General Brigham Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: